SecBot SecBot
PRESS-RELEASE ·Filed Jun 18, 2026

ALVO

Alvotech
BEARISH
Impact 6/10
Horizonimmediate Processed4mo ago WireGlobeNewswire
Press release · Offering
Actionable Insight ▼ Bearish

The offering provides near-term cash runway but significantly dilutes existing holders. Watch for the private placement close on June 25 and any subsequent capital needs. The increased float may pressure the stock in the near term.

DirectionBearish
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d ⚠ clustered
ALVO ▲ +28.06% at T+60d
SHORT call ✗ call lost -28.06% · α vs SPY -26.64% · entry $3.92 → $5.02
Entry = T+0 close
Jun 18, 2026
via day close
T+1d
-6.89%
call +6.89% · α +6.57%
$3.65
settled 4mo ago
T+5d
-11.22%
call +11.22% · α +9.56%
$3.48
settled 4mo ago
T+20d
-14.03%
call +14.03% · α +14.56%
$3.37
settled 3mo ago
T+60d
+28.06%
call -28.06% · α -26.64%
$5.02
settled 6w ago

Price Chart

Loading chart...

Executive Summary

Alvotech closed a $98M public offering of 26.1M shares at $3.75/share and concurrently announced a $67M private placement of 17.8M shares at the same price, for total gross proceeds of ~$165M. The combined issuance adds ~43.9M shares, diluting existing holders by ~12.7%. Proceeds will fund biosimilar development and general corporate purposes.

Key Financial Metrics

Deal Value
$165.0M

Key Facts

  • Closed public offering of 26,066,667 shares at $3.75, gross proceeds ~$98M.
  • Concurrent private placement of 17,826,666 shares at $3.75, expected gross ~$67M, closing on or about June 25, 2026.
  • Total gross proceeds ~$165M before expenses.
  • Post-private placement shares outstanding: 390,431,480, implying ~12.7% dilution.
  • Use of proceeds: biosimilar development, working capital, IP protection, capex, R&D, debt repayment.
  • Underwriters: BofA Securities, Jefferies, Evercore ISI.

Financial Impact

Dilution of ~12.7% for existing shareholders; $165M gross cash infusion at $3.75/share.

dilutioncashshare count

Risk Factors

  • Further dilution if additional offerings are needed to fund operations.
  • Execution risk on biosimilar pipeline development.
  • Potential stock price pressure from increased share supply.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
75% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3313996
28 reports for ALVO
Performance horizon
79% Hit rate @ T+20 11 of 14 directional calls Went positive at some point 17 of 18 best @ T+60▲ +60.61%Jul 1, 2026
Filters
Rows
Reports for ALVO — sortable, filterable
TypeNow
Oct 20, 2026
6d ago
6-K
BULLISH ★ 6/10
$5.12awaiting T+20—$4.62 (−9.77%)
Oct 14, 2026
12d ago
6-K
BULLISH ★ 7/10
$5.17awaiting T+20—$4.62 (−10.64%)
Oct 7, 2026
19d ago
6-K
NEUTRAL ★ 4/10
$5.85awaiting T+20—$4.62 (−21.03%)
Oct 5, 2026
21d ago
6-K
BULLISH ★ 6/10
$6.11awaiting T+20—$4.62 (−24.39%)
Oct 5, 2026
21d ago
Press Release
BULLISH ★ 7/10
$6.11awaiting T+20—$4.62 (−24.39%)
Aug 31, 2026
8w ago
6-K
BULLISH ★ 7/10
$5.19 $5.92▲ +14.07%▲ +14.44%$4.62 (−10.98%)
Aug 21, 2026
9w ago
6-K
BULLISH ★ 7/10
$4.43 $5.88▲ +32.73%▲ +31.72%$4.62 (+4.29%)
Aug 19, 2026
9w ago
Press Release
BEARISH ★ 6/10
$4.27 $5.87▼ −37.47%▼ −37.59%$4.62 (−8.20%)
Jul 29, 2026
12w ago
6-K
BULLISH ★ 7/10
$3.53 $4.91▲ +39.09%▲ +34.07%$4.62 (+30.88%)
Jul 3, 2026
16w ago
Press Release
NEUTRAL ★ 4/10
$3.46 $4.12▲ +19.08%▲ +19.64%$4.62 (+33.53%)
Showing 10 of 28

US Market Status

Market Closed — Opens in 5h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 18, 2026